Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials.

MRI-based selection for intra-arterial stroke therapy: value of pretreatment diffusion-weighted imaging lesion volume in selecting patients with acute stroke who will benefit from early recanalization. Stroke (2009) 1.94

Acute stroke magnetic resonance imaging: current status and future perspective. Neuroradiology (2009) 1.59

Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab (2010) 1.44

Imaging-based treatment selection for intravenous and intra-arterial stroke therapies: a comprehensive review. Expert Rev Cardiovasc Ther (2011) 1.14

Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry (2006) 1.09

Prospective study on the mismatch concept in acute stroke patients within the first 24 h after symptom onset - 1000Plus study. BMC Neurol (2009) 1.08

Dynamics of regional distribution of ischemic lesions in middle cerebral artery trunk occlusion relates to collateral circulation. J Cereb Blood Flow Metab (2010) 0.98

Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag (2009) 0.98

Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy. Stroke (2010) 0.98

Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. Br J Pharmacol (2007) 0.94

Thrombolysis, stroke-unit admission and early rehabilitation in elderly patients. Nat Rev Neurol (2009) 0.90

Clinical review: Imaging in ischaemic stroke--implications for acute management. Crit Care (2007) 0.86

Prognostic value of admission C-reactive protein in stroke patients undergoing iv thrombolysis. J Neurol (2008) 0.85

Are in-Hospital Delays Important Obstacles in Thrombolytic Therapy Following Acute Ischemic Stroke? J Clin Neurol (2007) 0.82

Intravenous administration of achyranthes bidentata polypeptides supports recovery from experimental ischemic stroke in vivo. PLoS One (2013) 0.81

The P2 receptor antagonist PPADS supports recovery from experimental stroke in vivo. PLoS One (2011) 0.81

MRI-guided selection of patients for treatment of acute ischemic stroke. Curr Opin Neurol (2014) 0.80

Atherosclerotic Peripheral Vascular Disease Symposium II: vascular magnetic resonance and computed tomographic imaging. Circulation (2008) 0.80

The economics of treating stroke as an acute brain attack. BMC Med (2009) 0.80

Outcome of MRI-based intravenous thrombolysis in carotid-T occlusion. J Neurol (2012) 0.79

A novel approach for mechanical tissue characterization indicates decreased elastic strength in brain areas affected by experimental thromboembolic stroke. Neuroreport (2015) 0.78

Fibrinolytic therapy in acute stroke. Curr Cardiol Rev (2010) 0.78

Safety and outcome of thrombolysis in mild stroke: a meta-analysis. Med Sci Monit (2014) 0.78

Predicting intracerebral hemorrhage by baseline magnetic resonance imaging in stroke patients undergoing systemic thrombolysis. Acta Neurol Scand (2014) 0.78

Hyperacute therapies for childhood stroke: a case report and review of the literature. Neurol Res Int (2010) 0.77

Future trials of endovascular mechanical recanalisation therapy in acute ischemic stroke patients: a position paper endorsed by ESMINT and ESNR : part I: Current situation and major research questions. Neuroradiology (2012) 0.77

Fibrinolysis and Beyond: Bridging the Gap between Local and Systemic Clot Removal. Front Neurol (2011) 0.75

Peripheral blood AKAP7 expression as an early marker for lymphocyte-mediated post-stroke blood brain barrier disruption. Sci Rep (2017) 0.75

Physiologic imaging in acute stroke: Patient selection. Interv Neuroradiol (2015) 0.75

Management of Acute Hypertensive Response in Patients With Ischemic Stroke. Neurohospitalist (2016) 0.75

Automated decision-support system for prediction of treatment responders in acute ischemic stroke. Front Neurol (2013) 0.75

Imaging patterns of venous-related brain injury in children. Pediatr Radiol (2017) 0.75

Mapping of cerebral metabolic rate of oxygen using dynamic susceptibility contrast and blood oxygen level dependent MR imaging in acute ischemic stroke. Neuroradiology (2015) 0.75

The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke. Stroke Vasc Neurol (2017) 0.75

[Baseline predictors of outcome in stroke patients treated with intravenous thrombolysis--the Austrian stroke unit registry]. Wien Med Wochenschr (2008) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74

Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58

Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33

Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol (2007) 6.15

Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01

Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med (2014) 5.79

One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61

Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00

Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ (2010) 4.74

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J (2011) 4.47

Ventral and dorsal pathways for language. Proc Natl Acad Sci U S A (2008) 4.32

Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet (2008) 4.14

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet (2010) 4.07

Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2008) 3.98

Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol (2008) 3.91

Dynamics of language reorganization after stroke. Brain (2006) 3.87

Nosocomial pneumonia after acute stroke: implications for neurological intensive care medicine. Stroke (2003) 3.53

Statistical analysis of the primary outcome in acute stroke trials. Stroke (2012) 3.52

Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21

DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol (2011) 3.18

Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke (2004) 3.07

Disconnection of speech-relevant brain areas in persistent developmental stuttering. Lancet (2002) 3.03

Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 3.03

Diffusion tensor imaging detects early Wallerian degeneration of the pyramidal tract after ischemic stroke. Neuroimage (2004) 2.80

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77

Broca's area and the language instinct. Nat Neurosci (2003) 2.69

Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke (2012) 2.64

Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol (2009) 2.64

Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology (2012) 2.60

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56

Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke (2007) 2.56

Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol (2008) 2.53

EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J (2013) 2.52

Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke (2013) 2.50

The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain (2012) 2.49

Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke (2013) 2.44

The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke (2006) 2.43

AGC1 deficiency associated with global cerebral hypomyelination. N Engl J Med (2009) 2.43

Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke (2003) 2.42

MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol (2006) 2.42

Sensitivity and interrater agreement of CT and diffusion-weighted MR imaging in hyperacute stroke. AJNR Am J Neuroradiol (2003) 2.41

Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke (2013) 2.36

Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke (2007) 2.36

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace (2015) 2.35

Comparison of CT and CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke (2002) 2.33

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation (2010) 2.27

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke (2004) 2.24

Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke (2008) 2.24

Comparison of perfusion computed tomography and computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke of less than 6 hours' duration. Stroke (2004) 2.24

Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro MR imaging. Radiology (2009) 2.23

Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits MMP-9-mediated blood-brain-barrier breakdown in a mouse model for ischemic stroke. Circ Res (2013) 2.21

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol (2013) 2.17

Extracellular concentrations of non-transmitter amino acids in peri-infarct tissue of patients predict malignant middle cerebral artery infarction. Stroke (2003) 2.15

MR mismatch is useful for patient selection for thrombolysis: yes. Stroke (2009) 2.13

Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke (2005) 2.13

Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. Stroke (2013) 2.11

Smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke. Stroke (2013) 2.11

Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J (2008) 2.09

Perfusion-weighted imaging/diffusion-weighted imaging mismatch on MRI can now be used to select patients for recombinant tissue plasminogen activator beyond 3 hours: pro. Stroke (2005) 2.06

Fluid-attenuated inversion recovery evolution within 12 hours from stroke onset: a reliable tissue clock? Stroke (2009) 1.99

Surgical decompression of patients with large middle cerebral artery infarcts is effective. Stroke (2003) 1.98

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA (2010) 1.97